touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer‘ (ABSTRACT NUMBER: GS3-01) was presented at the virtual SABCS 2020, 8-11 December 2020.
Questions
- What has been the impact of pembrolizumab on the treatment of patients with triple-negative breast cancer? (0:19)
- Could you tell us a little about the KEYNOTE-355 study and its findings? (1:02)
- What additional efficacy endpoints are you presenting at SABCS 2020? (1:58)
- How do these findings compare to those for pembrolizumab monotherapy in the same treatment setting? (3:28)
- How will tumour PD-L1 expression combined positive score (CPS) be used to make decisions in patients with previously untreated locally advanced or metastatic triple-negative breast cancer? (4:45)
Speaker Disclosures: Consulting/Advisor: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim and Kyowa Kirin; Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo; Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; Stock, patents and intellectual property: MedSIR; Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer and Daiichi Sankyo.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the San Antonio Breast Cancer Symposium (SABCS) 2020.
PDL1 = programmed death-ligand 1.
